$AEON
AEON Biopharma, Inc. Stock $aeon

$aeon Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000183760724000063 Filed on May 14, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue			$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.321M	$4.649M	$3.841M
YoY Change	-32.85%	21.04%
% of Gross Profit
Research & Development	$4.439M	$5.732M	$9.205M
YoY Change	-50.81%	-37.73%
% of Gross Profit
Depreciation & Amortization		$25.00K	$25.00K
YoY Change		0.0%
% of Gross Profit
Operating Expenses	-$153.5M	$74.15M	$1.743M
YoY Change	-4447.68%	4152.96%	348.12%
Operating Profit	$153.5M	-$74.15M	-$1.743M
YoY Change	-4451.97%	4152.98%	348.11%
Interest Expense			$1.560M
YoY Change			-50.69%
% of Operating Profit
Other Income/Expense, Net	$10.64M	-$43.87M	$1.760M
YoY Change	-3382.08%	-2593.06%	-44.36%
Pretax Income	$164.1M	-$118.0M	$16.12K
YoY Change	-4361.9%	-732267.01%	-99.42%
Income Tax			$404.6K
% Of Pretax Income			2510.29%
Net Earnings	$164.1M	-$118.0M	-$388.5K
YoY Change	-4262.81%	30276.69%	-114.01%
Net Earnings / Revenue
Basic Earnings Per Share	$4.22	-$3.17	-$0.13
Diluted Earnings Per Share	$4.22	-$3.17	-$0.02
COMMON SHARES
Basic Shares Outstanding	39.12M	37.79M	138.8M
Diluted Shares Outstanding	38.84M	37.27M	138.8M

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments			$457.1K
YoY Change			174.96%
Cash & Equivalents	$3.400M	$1.558M	$457.1K
Short-Term Investments
Other Short-Term Assets			$85.29K
YoY Change			-75.79%
Inventory
Prepaid Expenses			$85.29K
Receivables
Other Receivables
Total Short-Term Assets	$4.019M	$2.498M	$542.4K
YoY Change	578.77%	360.56%	4.6%
LONG-TERM ASSETS
Property, Plant & Equipment	$282.0K	$307.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$21.07M
YoY Change			-92.37%
Other Assets	$29.00K	$29.00K
YoY Change
Total Long-Term Assets	$1.715M	$534.0K	$21.07M
YoY Change	-91.91%	-97.47%	-92.37%
TOTAL ASSETS
Total Short-Term Assets	$4.019M	$2.498M	$542.4K
Total Long-Term Assets	$1.715M	$534.0K	$21.07M
Total Assets	$5.734M	$3.032M	$21.62M
YoY Change	-73.68%	-85.97%	-92.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.030M	$6.523M	$3.981M
YoY Change	-56.71%	63.85%	436.66%
Accrued Expenses			$454.1K
YoY Change			808.18%
Deferred Revenue
YoY Change
Short-Term Debt			$150.0K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$10.43M	$15.96M	$5.873M
YoY Change	10.23%	171.69%	641.71%
LONG-TERM LIABILITIES
Long-Term Debt			$0.00
YoY Change
Other Long-Term Liabilities			$2.068M
YoY Change			-85.24%
Total Long-Term Liabilities			$2.068M
YoY Change			-85.24%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.43M	$15.96M	$5.873M
Total Long-Term Liabilities			$2.068M
Total Liabilities	$33.68M	$201.4M	$7.942M
YoY Change	179.43%	2436.17%	-46.35%
SHAREHOLDERS EQUITY
Retained Earnings	-$427.5M	-$591.6M	-$7.351M
YoY Change	3619.37%	7948.28%	-48.2%
Common Stock	$4.000K	$4.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity			-$7.318M
YoY Change
Total Liabilities & Shareholders Equity	$5.734M	$3.032M	$21.62M
YoY Change	-73.68%	-85.97%	-92.19%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	$164.1M	-$118.0M	-$388.5K
YoY Change	-4262.81%	30276.69%	-114.01%
Depreciation, Depletion And Amortization		$25.00K	$25.00K
YoY Change		0.0%
Cash From Operating Activities		-$8.600M	-$623.9K
YoY Change		1278.36%	51.56%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities			$260.0M
YoY Change			322897.54%
Cash From Investing Activities			$260.0M
YoY Change			322897.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		5.000M	-259.0M
YoY Change		-101.93%
NET CHANGE
Cash From Operating Activities		-8.600M	-623.9K
Cash From Investing Activities			260.0M
Cash From Financing Activities		5.000M	-259.0M
Net Change In Cash		-3.600M	389.2K
YoY Change		-1025.03%	-217.52%
FREE CASH FLOW
Cash From Operating Activities		-$8.600M	-$623.9K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P8M12D
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38120288
CY2023Q3	aeon	Change In Amount Of Contingent Consideration Liability ChangeInAmountOfContingentConsiderationLiability	-69715000
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2023Q1	us-gaap	Debt Instrument Measurement Input Extensible List DebtInstrumentMeasurementInputExtensibleList	http://fasb.org/us-gaap/2023#MeasurementInputDiscountRateMember
CY2024Q1	us-gaap	Debt Instrument Measurement Input Extensible List DebtInstrumentMeasurementInputExtensibleList	http://fasb.org/us-gaap/2023#MeasurementInputDiscountRateMember
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001837607
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-40021
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	AEON Biopharma, Inc.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-3940478
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	5 Park Plaza
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1750
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Irvine
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92614
CY2024Q1	dei	City Area Code CityAreaCode	949
CY2024Q1	dei	City Area Code CityAreaCode	949
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	354-6499
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	354-6499
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Security12b Title Security12bTitle	Class A common stock, $0.0001 par value per share
CY2024Q1	dei	Security12b Title Security12bTitle	Class A common stock, $0.0001 par value per share
CY2024Q1	dei	Trading Symbol TradingSymbol	AEON
CY2024Q1	dei	Trading Symbol TradingSymbol	AEON
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	39122238
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	39122238
CY2024Q1	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2024Q1	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2023	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2023	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1558000
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1558000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5158000
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	940000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1064000
CY2024Q1	us-gaap	Assets Current AssetsCurrent	2498000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	6222000
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	307000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	332000
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	198000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	262000
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	29000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	29000
CY2024Q1	us-gaap	Assets Assets	3032000
CY2023Q4	us-gaap	Assets Assets	6845000
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	6523000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3388000
CY2024Q1	aeon	Accrued Clinical Trails Expenses Current AccruedClinicalTrailsExpensesCurrent	984000
CY2023Q4	aeon	Accrued Clinical Trails Expenses Current AccruedClinicalTrailsExpensesCurrent	5128000
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1338000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	943000
CY2024Q1	aeon	Forward Purchase Agreements Liquidated Damages Current ForwardPurchaseAgreementsLiquidatedDamagesCurrent	3000000
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4112000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3590000
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	15957000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13049000
CY2024Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	5087000
CY2024Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	12000000
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1447000
CY2024Q1	aeon	Contingent Consideration Liability ContingentConsiderationLiability	168119000
CY2023Q4	aeon	Contingent Consideration Liability ContingentConsiderationLiability	104350000
CY2024Q1	aeon	Forward Purchase Agreement And Derivative Liability ForwardPurchaseAgreementAndDerivativeLiability	250000
CY2023Q4	us-gaap	Liabilities Liabilities	159889000
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38120288
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38120288
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	381264000
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-591620000
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-198381000
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-153044000
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3032000
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4649000
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9205000
CY2024Q1	aeon	Change In Amount Of Contingent Consideration Liability ChangeInAmountOfContingentConsiderationLiability	63769000
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	74150000
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	13046000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5158000
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	940000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1064000
CY2024Q1	us-gaap	Assets Current AssetsCurrent	2498000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	6222000
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	307000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	332000
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	198000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	262000
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	29000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	29000
CY2024Q1	us-gaap	Assets Assets	3032000
CY2023Q4	us-gaap	Assets Assets	6845000
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	6523000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3388000
CY2024Q1	aeon	Accrued Clinical Trails Expenses Current AccruedClinicalTrailsExpensesCurrent	984000
CY2023Q4	aeon	Accrued Clinical Trails Expenses Current AccruedClinicalTrailsExpensesCurrent	5128000
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1338000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	943000
CY2024Q1	aeon	Forward Purchase Agreements Liquidated Damages Current ForwardPurchaseAgreementsLiquidatedDamagesCurrent	3000000
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4112000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3590000
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	15957000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13049000
CY2024Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	5087000
CY2024Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	12000000
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1447000
CY2024Q1	aeon	Contingent Consideration Liability ContingentConsiderationLiability	168119000
CY2023Q4	aeon	Contingent Consideration Liability ContingentConsiderationLiability	104350000
CY2024Q1	aeon	Forward Purchase Agreement And Derivative Liability ForwardPurchaseAgreementAndDerivativeLiability	250000
CY2023Q4	aeon	Forward Purchase Agreement And Derivative Liability ForwardPurchaseAgreementAndDerivativeLiability	41043000
CY2024Q1	us-gaap	Liabilities Liabilities	201413000
CY2023Q4	us-gaap	Liabilities Liabilities	159889000
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38120288
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38120288
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37159600
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37159600
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	4000
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	4000
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	393235000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	381264000
CY2023Q4	aeon	Subscription Receivables SubscriptionReceivables	-60710000
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-591620000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-473602000
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-198381000
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-153044000
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3032000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6845000
CY2024Q1	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2023Q1	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Predecessor
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4649000
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3841000
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5732000
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9205000
CY2024Q1	aeon	Change In Amount Of Contingent Consideration Liability ChangeInAmountOfContingentConsiderationLiability	63769000
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	74150000
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	13046000
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-74150000
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-13046000
CY2023Q1	aeon	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	-4657000
CY2024Q1	aeon	Change In Fair Value Of Forward Purchase Agreement And Derivative ChangeInFairValueOfForwardPurchaseAgreementAndDerivative	22917000
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	39000
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	64000
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-43868000
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4593000
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-118018000
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17639000
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.17
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.17
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37268074
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37268074
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	138825356
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	138825356
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-153044000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-118018000
CY2024Q1	aeon	Termination Of Forward Purchase Agreements TerminationOfForwardPurchaseAgreements	60710000
CY2024Q1	aeon	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	10350000
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1621000
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-198381000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-270413000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-17639000
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1360000
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-286692000
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-118018000
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-17639000
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	25000
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	25000
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1621000
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1360000
CY2024Q1	aeon	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	-87000
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-74150000
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-13046000
CY2024Q1	aeon	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	-87000
CY2023Q1	aeon	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	-4657000
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	20903000
CY2024Q1	aeon	Change In Fair Value Of Forward Purchase Agreement And Derivative ChangeInFairValueOfForwardPurchaseAgreementAndDerivative	22917000
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	64000
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-118018000
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17639000
CY2024Q1	aeon	Loss And Comprehensive Loss LossAndComprehensiveLoss	-118018000
CY2023Q1	aeon	Loss And Comprehensive Loss LossAndComprehensiveLoss	-17639000
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.17
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	138825356
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-153044000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-118018000
CY2024Q1	aeon	Termination Of Forward Purchase Agreements TerminationOfForwardPurchaseAgreements	60710000
CY2024Q1	aeon	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	10350000
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-198381000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-270413000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-17639000
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1360000
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-118018000
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-17639000
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	25000
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1621000
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1360000
CY2023Q1	aeon	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	-4657000
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	20903000
CY2024Q1	aeon	Change In Fair Value Of Forward Purchase Agreement And Derivative ChangeInFairValueOfForwardPurchaseAgreementAndDerivative	22917000
CY2024Q1	aeon	Change In Amount Of Contingent Consideration Liability ChangeInAmountOfContingentConsiderationLiability	63769000
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-124000
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-39000
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3136000
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3524000
CY2024Q1	aeon	Increase Decrease In Accrued Expenses And Other Liabilities IncreaseDecreaseInAccruedExpensesAndOtherLiabilities	-3228000
CY2023Q1	aeon	Increase Decrease In Accrued Expenses And Other Liabilities IncreaseDecreaseInAccruedExpensesAndOtherLiabilities	3984000
CY2024Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-64000
CY2023Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-40000
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8600000
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11058000
CY2024Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	5000000
CY2023Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	6000000
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5000000
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6000000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3600000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5058000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5158000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9746000
CY2023Q1	aeon	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	-4657000
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	20903000
CY2024Q1	aeon	Change In Fair Value Of Forward Purchase Agreement And Derivative ChangeInFairValueOfForwardPurchaseAgreementAndDerivative	22917000
CY2024Q1	aeon	Change In Amount Of Contingent Consideration Liability ChangeInAmountOfContingentConsiderationLiability	63769000
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-124000
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-39000
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3136000
CY2024Q1	aeon	Increase Decrease In Accrued Expenses And Other Liabilities IncreaseDecreaseInAccruedExpensesAndOtherLiabilities	-3228000
CY2023Q1	aeon	Increase Decrease In Accrued Expenses And Other Liabilities IncreaseDecreaseInAccruedExpensesAndOtherLiabilities	3984000
CY2024Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-64000
CY2023Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-40000
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8600000
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11058000
CY2024Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	5000000
CY2023Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	6000000
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5000000
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6000000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3600000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5058000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5158000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9746000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1558000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4688000
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-591600000
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37268074
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37268074
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.17
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.17
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3524000
CY2024Q1	aeon	Increase Decrease In Accrued Expenses And Other Liabilities IncreaseDecreaseInAccruedExpensesAndOtherLiabilities	-3228000
CY2023Q1	aeon	Increase Decrease In Accrued Expenses And Other Liabilities IncreaseDecreaseInAccruedExpensesAndOtherLiabilities	3984000
CY2024Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-64000
CY2023Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-40000
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8600000
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11058000
CY2024Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	5000000
CY2023Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	6000000
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5000000
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6000000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3600000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5058000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5158000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9746000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1558000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4688000
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-591600000
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes. The Company’s most significant estimates relate to the research and development accruals, valuation of common stock and related stock-</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">based compensation, and the fair values of the contingent consideration, forward purchase agreements, in-process research and development, warrant liabilities, convertible notes, among others. Although the Company bases estimates on historical experience, knowledge of current events and actions it may undertake in the future, and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments over the carrying values of assets and liabilities, this process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.</p>
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37268074
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1558000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4688000
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-591600000
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-591600000
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.17
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.17
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes. The Company’s most significant estimates relate to the research and development accruals, valuation of common stock and related stock-</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">based compensation, and the fair values of the contingent consideration, forward purchase agreements, in-process research and development, warrant liabilities, convertible notes, among others. Although the Company bases estimates on historical experience, knowledge of current events and actions it may undertake in the future, and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments over the carrying values of assets and liabilities, this process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.</p>
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risk and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks common to early-stage companies in the pharmaceutical industry including, but not limited to, dependency on the clinical and commercial success of its current and any future product candidates, ability to obtain regulatory approval of its current and any future product candidates, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients and significant competition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company relies on Daewoong Pharmaceutical Co., LTD. (“Daewoong”), a South Korean pharmaceutical manufacturer, as an exclusive and sole supplier to manufacture the Company’s source material for product candidates. Any termination or loss of significant rights, including exclusivity, under the Company’s license and supply agreement with Daewoong (the “Daewoong Agreement”) would materially and adversely affect the Company’s commercialization of its products. See <a href="#Note7_Commitments_Contingencies"><span style="font-style:normal;font-weight:normal;">Note 7 Commitments and Contingencies</span></a> for a discussion of the Daewoong Agreement.</p>
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes. The Company’s most significant estimates relate to the research and development accruals, valuation of common stock and related stock-</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">based compensation, and the fair values of the contingent consideration, forward purchase agreements, in-process research and development, warrant liabilities, convertible notes, among others. Although the Company bases estimates on historical experience, knowledge of current events and actions it may undertake in the future, and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments over the carrying values of assets and liabilities, this process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.</p>
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risk and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks common to early-stage companies in the pharmaceutical industry including, but not limited to, dependency on the clinical and commercial success of its current and any future product candidates, ability to obtain regulatory approval of its current and any future product candidates, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients and significant competition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company relies on Daewoong Pharmaceutical Co., LTD. (“Daewoong”), a South Korean pharmaceutical manufacturer, as an exclusive and sole supplier to manufacture the Company’s source material for product candidates. Any termination or loss of significant rights, including exclusivity, under the Company’s license and supply agreement with Daewoong (the “Daewoong Agreement”) would materially and adversely affect the Company’s commercialization of its products. See <a href="#Note7_Commitments_Contingencies"><span style="font-style:normal;font-weight:normal;">Note 7 Commitments and Contingencies</span></a> for a discussion of the Daewoong Agreement.</p>
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes. The Company’s most significant estimates relate to the research and development accruals, valuation of common stock and related stock-</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">based compensation, and the fair values of the contingent consideration, forward purchase agreements, in-process research and development, warrant liabilities, convertible notes, among others. Although the Company bases estimates on historical experience, knowledge of current events and actions it may undertake in the future, and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments over the carrying values of assets and liabilities, this process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.</p>
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risk and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks common to early-stage companies in the pharmaceutical industry including, but not limited to, dependency on the clinical and commercial success of its current and any future product candidates, ability to obtain regulatory approval of its current and any future product candidates, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients and significant competition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company relies on Daewoong Pharmaceutical Co., LTD. (“Daewoong”), a South Korean pharmaceutical manufacturer, as an exclusive and sole supplier to manufacture the Company’s source material for product candidates. Any termination or loss of significant rights, including exclusivity, under the Company’s license and supply agreement with Daewoong (the “Daewoong Agreement”) would materially and adversely affect the Company’s commercialization of its products. See <a href="#Note7_Commitments_Contingencies"><span style="font-style:normal;font-weight:normal;">Note 7 Commitments and Contingencies</span></a> for a discussion of the Daewoong Agreement.</p>
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	502000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	502000
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	195000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	170000
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	307000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	332000
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17639000
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	502000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	502000
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	195000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	170000
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	307000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	332000
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17639000
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-17639000
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	502000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	502000
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	195000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	170000
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	307000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	332000
CY2024Q1	us-gaap	Legal Fees LegalFees	2325000
CY2023	us-gaap	Legal Fees LegalFees	1867000
CY2024Q1	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	569000
CY2023Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	569000
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	205000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	278000
CY2024Q1	aeon	Third Party Usage Liabilities Current ThirdPartyUsageLiabilitiesCurrent	25000
CY2023Q4	aeon	Third Party Usage Liabilities Current ThirdPartyUsageLiabilitiesCurrent	33000
CY2024Q1	aeon	Remaining Other Accrued Liabilities RemainingOtherAccruedLiabilities	988000
CY2023Q4	aeon	Remaining Other Accrued Liabilities RemainingOtherAccruedLiabilities	843000
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4112000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3590000
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-17639000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-118018000
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	502000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	502000
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	195000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	170000
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	307000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	332000
CY2023	us-gaap	Legal Fees LegalFees	1867000
CY2024Q1	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	569000
CY2023Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	569000
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	205000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	278000
CY2024Q1	aeon	Third Party Usage Liabilities Current ThirdPartyUsageLiabilitiesCurrent	25000
CY2023Q4	aeon	Third Party Usage Liabilities Current ThirdPartyUsageLiabilitiesCurrent	33000
CY2024Q1	aeon	Remaining Other Accrued Liabilities RemainingOtherAccruedLiabilities	988000
CY2023Q4	aeon	Remaining Other Accrued Liabilities RemainingOtherAccruedLiabilities	843000
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4112000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3590000
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	138825356
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	138825356
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2024Q1	us-gaap	Legal Fees LegalFees	2325000
CY2023	us-gaap	Legal Fees LegalFees	1867000
CY2024Q1	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	569000
CY2023Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	569000
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	205000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	278000
CY2024Q1	aeon	Third Party Usage Liabilities Current ThirdPartyUsageLiabilitiesCurrent	25000
CY2023Q4	aeon	Third Party Usage Liabilities Current ThirdPartyUsageLiabilitiesCurrent	33000
CY2024Q1	aeon	Remaining Other Accrued Liabilities RemainingOtherAccruedLiabilities	988000
CY2023Q4	aeon	Remaining Other Accrued Liabilities RemainingOtherAccruedLiabilities	843000
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4112000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3590000
CY2024Q1	us-gaap	Legal Fees LegalFees	2325000
CY2023	us-gaap	Legal Fees LegalFees	1867000
CY2024Q1	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	569000
CY2023Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	569000
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	205000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	278000
CY2024Q1	aeon	Third Party Usage Liabilities Current ThirdPartyUsageLiabilitiesCurrent	25000
CY2023Q4	aeon	Third Party Usage Liabilities Current ThirdPartyUsageLiabilitiesCurrent	33000
CY2024Q1	aeon	Remaining Other Accrued Liabilities RemainingOtherAccruedLiabilities	988000
CY2023Q4	aeon	Remaining Other Accrued Liabilities RemainingOtherAccruedLiabilities	843000
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4112000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3590000
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-118018000
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17639000
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-17639000
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	138825356
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37268074
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17639000
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-17639000
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	138825356
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	138825356
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37268074
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	33262983
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	31294609
CY2024Q1	aeon	Changes In Fair Value Of Convertible Notes ChangesInFairValueOfConvertibleNotes	100000
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	33262983
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	31294609
CY2023Q3	aeon	Number Of Shares To Be Received Prior To Merger NumberOfSharesToBeReceivedPriorToMerger	2.328
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	33262983
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	31294609
CY2023Q3	aeon	Number Of Shares To Be Received Prior To Merger NumberOfSharesToBeReceivedPriorToMerger	2.328
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	33262983
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	31294609
CY2023Q3	aeon	Number Of Shares To Be Received Prior To Merger NumberOfSharesToBeReceivedPriorToMerger	2.328
CY2024Q1	aeon	Changes In Fair Value Of Convertible Notes ChangesInFairValueOfConvertibleNotes	100000
CY2024Q1	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	5100000
CY2023Q1	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	0
CY2024Q1	aeon	Subscription Receivable And Derivative Liability SubscriptionReceivableAndDerivativeLiability	20300000
CY2023Q2	aeon	Number Of Additional Shares To Be Issued NumberOfAdditionalSharesToBeIssued	16000000
CY2023Q2	aeon	Threshold Increase In Episodic Migraine Contingent Consideration Shares ThresholdIncreaseInEpisodicMigraineContingentConsiderationShares	11000000
CY2023Q2	aeon	Number Of Contingent Consideration Shares To Be Issued Upon Threshold Increase In Episodic Migraine Contingent Consideration Shares NumberOfContingentConsiderationSharesToBeIssuedUponThresholdIncreaseInEpisodicMigraineContingentConsiderationShares	0
CY2023Q2	aeon	Reduction In Number Of Chronic Migraine Contingent Consideration Shares If Product Licenses Given Before Satisfaction Of Issuance Of Shares ReductionInNumberOfChronicMigraineContingentConsiderationSharesIfProductLicensesGivenBeforeSatisfactionOfIssuanceOfShares	1000000
CY2024Q1	aeon	Stock Issued During Period Shares Warrants Exercised StockIssuedDuringPeriodSharesWarrantsExercised	960688
CY2024Q1	aeon	Adjustments To Additional Paid In Capital Cashless Exercise Of Warrants AdjustmentsToAdditionalPaidInCapitalCashlessExerciseOfWarrants	10300000
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	14479999000
CY2024Q1	aeon	Changes In Fair Value Of Convertible Notes ChangesInFairValueOfConvertibleNotes	100000
CY2024Q1	us-gaap	Convertible Debt ConvertibleDebt	5000000.0
CY2024Q1	aeon	Subscription Receivable And Derivative Liability SubscriptionReceivableAndDerivativeLiability	20300000
CY2023Q2	aeon	Number Of Additional Shares To Be Issued NumberOfAdditionalSharesToBeIssued	16000000
CY2023Q2	aeon	Threshold Increase In Episodic Migraine Contingent Consideration Shares ThresholdIncreaseInEpisodicMigraineContingentConsiderationShares	11000000
CY2023Q2	aeon	Number Of Chronic Migraine Contingent Consideration Shares By Increase In Episodic Migraine Contingent Consideration Shares NumberOfChronicMigraineContingentConsiderationSharesByIncreaseInEpisodicMigraineContingentConsiderationShares	0
CY2023Q2	aeon	Number Of Contingent Consideration Shares To Be Issued Upon Threshold Increase In Episodic Migraine Contingent Consideration Shares NumberOfContingentConsiderationSharesToBeIssuedUponThresholdIncreaseInEpisodicMigraineContingentConsiderationShares	0
CY2023Q2	aeon	Reduction In Number Of Chronic Migraine Contingent Consideration Shares If Product Licenses Given Before Satisfaction Of Issuance Of Shares ReductionInNumberOfChronicMigraineContingentConsiderationSharesIfProductLicensesGivenBeforeSatisfactionOfIssuanceOfShares	1000000
CY2023Q2	aeon	Minimum Number Of Chronic Migraine Contingent Consideration Shares After Reduction MinimumNumberOfChronicMigraineContingentConsiderationSharesAfterReduction	0
CY2024Q1	aeon	Stock Issued During Period Shares Warrants Exercised StockIssuedDuringPeriodSharesWarrantsExercised	960688
CY2024Q1	aeon	Adjustments To Additional Paid In Capital Cashless Exercise Of Warrants AdjustmentsToAdditionalPaidInCapitalCashlessExerciseOfWarrants	10300000
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	14479999000
CY2024Q1	aeon	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	-6203914000
CY2024Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	8276085000
CY2021Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P3Y
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	213000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	213000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	8000
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	205000
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	205000
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	198000
CY2024Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.10
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	43000
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	60000
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	80000
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	77000
CY2023Q3	aeon	Deferred Underwriting Fee DeferredUnderwritingFee	1250000
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2024Q1	aeon	Changes In Fair Value Of Convertible Notes ChangesInFairValueOfConvertibleNotes	100000
CY2023Q1	aeon	Changes In Fair Value Of Convertible Notes ChangesInFairValueOfConvertibleNotes	4700000
CY2024Q1	us-gaap	Convertible Debt ConvertibleDebt	5000000.0
CY2023Q1	us-gaap	Convertible Debt ConvertibleDebt	0
CY2024Q1	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	5100000
CY2023Q1	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	0
CY2024Q1	aeon	Subscription Receivable And Derivative Liability SubscriptionReceivableAndDerivativeLiability	20300000
CY2023Q2	aeon	Number Of Additional Shares To Be Issued NumberOfAdditionalSharesToBeIssued	16000000
CY2023Q2	aeon	Threshold Increase In Episodic Migraine Contingent Consideration Shares ThresholdIncreaseInEpisodicMigraineContingentConsiderationShares	11000000
CY2023Q2	aeon	Number Of Contingent Consideration Shares To Be Issued Upon Threshold Increase In Episodic Migraine Contingent Consideration Shares NumberOfContingentConsiderationSharesToBeIssuedUponThresholdIncreaseInEpisodicMigraineContingentConsiderationShares	0
CY2023Q2	aeon	Reduction In Number Of Chronic Migraine Contingent Consideration Shares If Product Licenses Given Before Satisfaction Of Issuance Of Shares ReductionInNumberOfChronicMigraineContingentConsiderationSharesIfProductLicensesGivenBeforeSatisfactionOfIssuanceOfShares	1000000
CY2023Q2	aeon	Minimum Number Of Chronic Migraine Contingent Consideration Shares After Reduction MinimumNumberOfChronicMigraineContingentConsiderationSharesAfterReduction	0
CY2024Q1	aeon	Stock Issued During Period Shares Warrants Exercised StockIssuedDuringPeriodSharesWarrantsExercised	960688
CY2024Q1	aeon	Adjustments To Additional Paid In Capital Cashless Exercise Of Warrants AdjustmentsToAdditionalPaidInCapitalCashlessExerciseOfWarrants	10300000
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	14479999000
CY2024Q1	aeon	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	-6203914000
CY2021Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P3Y
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	213000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	213000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	8000
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	205000
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	205000
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	198000
CY2024Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.10
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38120288
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.47
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.50
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.74
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.80
CY2023Q1	aeon	Changes In Fair Value Of Convertible Notes ChangesInFairValueOfConvertibleNotes	4700000
CY2024Q1	us-gaap	Convertible Debt ConvertibleDebt	5000000.0
CY2024Q1	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	5100000
CY2023Q1	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	0
CY2024Q1	aeon	Subscription Receivable And Derivative Liability SubscriptionReceivableAndDerivativeLiability	20300000
CY2023Q2	aeon	Number Of Additional Shares To Be Issued NumberOfAdditionalSharesToBeIssued	16000000
CY2023Q2	aeon	Number Of Contingent Consideration Shares To Be Issued Upon Threshold Increase In Episodic Migraine Contingent Consideration Shares NumberOfContingentConsiderationSharesToBeIssuedUponThresholdIncreaseInEpisodicMigraineContingentConsiderationShares	0
CY2023Q2	aeon	Reduction In Number Of Chronic Migraine Contingent Consideration Shares If Product Licenses Given Before Satisfaction Of Issuance Of Shares ReductionInNumberOfChronicMigraineContingentConsiderationSharesIfProductLicensesGivenBeforeSatisfactionOfIssuanceOfShares	1000000
CY2024Q1	aeon	Stock Issued During Period Shares Warrants Exercised StockIssuedDuringPeriodSharesWarrantsExercised	960688
CY2024Q1	aeon	Adjustments To Additional Paid In Capital Cashless Exercise Of Warrants AdjustmentsToAdditionalPaidInCapitalCashlessExerciseOfWarrants	10300000
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	14479999000
CY2024Q1	aeon	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	-6203914000
CY2024Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	8276085000
CY2021Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P3Y
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	213000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	213000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	8000
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	205000
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	205000
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	198000
CY2024Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.10
CY2024Q1	aeon	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	-6203914000
CY2021Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P3Y
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	213000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	213000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	8000
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	205000
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	205000
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	198000
CY2024Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.10
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	43000
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	77000
CY2023Q3	aeon	Deferred Underwriting Fee DeferredUnderwritingFee	1250000
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one
CY2024Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	33160907
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	38876675
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	43000
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	60000
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	80000
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	77000
CY2023Q3	aeon	Deferred Underwriting Fee DeferredUnderwritingFee	1250000
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38120288
CY2024Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	0
CY2024Q1	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one
CY2024Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	33160907
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	38876675
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.47
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.74
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.80
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.041
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.043
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0361
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0366
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	43000
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	60000
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	80000
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	77000
CY2023Q3	aeon	Deferred Underwriting Fee DeferredUnderwritingFee	1250000
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38120288
CY2024Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	0
CY2024Q1	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one
CY2024Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	33160907
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	38876675
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.47
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.50
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.74
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.80
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.041
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.043
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0361
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0366
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.47
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.50
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.74
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.80
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.041
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.043
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0361
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0366
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.041
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.043
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0361
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0366
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001837607-24-000063-index-headers.html	Edgar Link	pending
0001837607-24-000063-index.html	Edgar Link	pending
0001837607-24-000063.txt	Edgar Link	pending
0001837607-24-000063-xbrl.zip	Edgar Link	pending
aeon-20240331.xsd	Edgar Link	pending
aeon-20240331x10q.htm	Edgar Link	pending
aeon-20240331xex31d1.htm	Edgar Link	pending
aeon-20240331xex31d2.htm	Edgar Link	pending
aeon-20240331xex32d1.htm	Edgar Link	pending
aeon-20240331xex32d2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
aeon-20240331_pre.xml	Edgar Link	unprocessable
0001837607-24-000063-index-headers.html	Edgar Link	pending
0001837607-24-000063-index.html	Edgar Link	pending
0001837607-24-000063.txt	Edgar Link	pending
0001837607-24-000063-xbrl.zip	Edgar Link	pending
aeon-20240331.xsd	Edgar Link	pending
aeon-20240331x10q.htm	Edgar Link	pending
aeon-20240331xex31d1.htm	Edgar Link	pending
aeon-20240331xex31d2.htm	Edgar Link	pending
aeon-20240331xex32d1.htm	Edgar Link	pending
aeon-20240331xex32d2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
aeon-20240331_lab.xml	Edgar Link	unprocessable
aeon-20240331x10q_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
aeon-20240331_pre.xml	Edgar Link	unprocessable
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
aeon-20240331_cal.xml	Edgar Link	unprocessable
aeon-20240331_def.xml	Edgar Link	unprocessable
aeon-20240331_lab.xml	Edgar Link	unprocessable
aeon-20240331_cal.xml	Edgar Link	unprocessable
aeon-20240331_def.xml	Edgar Link	unprocessable
aeon-20240331x10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AEON
AEON Biopharma, Inc. Stock $aeon

2024 Q2 Form 10-Q Financial Statement

#000183760724000063 Filed on May 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AEON AEON Biopharma, Inc. Stock $aeon

2024 Q2 Form 10-Q Financial Statement

#000183760724000063 Filed on May 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AEON
AEON Biopharma, Inc. Stock $aeon